Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 10.98%
As of Wednesday, August 19, Aardvark Therapeutics, Inc.’s AARD share price has surged by 10.98%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Commentary & Analysis
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 6.08%
As of Tuesday, August 18, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 5.96%
As of Monday, August 17, Aardvark Therapeutics, Inc.’s AARD share price has surged by 5.96%, which has investors questioning if this is right time to sell.Michael Rose
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 11.24%
As of Tuesday, August 11, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 11.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 8.10%
As of Monday, August 10, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 8.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | AARD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $128.9 | $618.0 | 24% |
|
| Shares Out (Mil) | 21.8 | 44.8 | 31% |
|
| Institutional Ownership | 49.0% | 85.3% | 23% |
|
| Float (Mil) | 10.9 | 47.4 | 20% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 137 | 390 | 39% |
|
| Price Change (52-week) |
(42.1%) | 68.6% | 18% |
|
| Growth | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 9 | |
| Current EPS | ($0.772) | ($3.168) | ($2.782) | |
| Month Ago EPS | ($0.876) | ($3.668) | ($3.098) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.869) | ($3.651) | ($3.238) | |
| Year/Year Chg | 17.1% | 7.9% | (17.6%) | |
| Financials | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($70) | ($11) | 14% |
|
| EPS (TTM) | ($3.205) | ($0.700) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $5 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $71 | $450 | 19% |
|
| Valuation | AARD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.78 | 45% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AARD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (61.1%) | (22.4%) | 9% |
|
| ROE | (66.0%) | (20.2%) | 13% |
|
| Liabilities to Assets | 8.2% | 32.2% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Aardvark Therapeutics, Inc. did not pass any screens on 8/20/2026.
